# Study C3441021 Clinical Trial Assay

CAUTION—Investigational Device. Limited by Federal (or United States) law to investigational use.

*For performance evaluation only - the results provided in this report are for investigational use only to determine eligibility for C3441021*

STUDY
Partner Name **Pfizer Inc.**
Partner Study ID **C3441021**
FMI Study ID **F1S-BPA-PRO-17-625**

TEST
FMI Test Order # **ORD-0941933-01**
Test Type **FoundationOne DX1 (SOLID)**
Report Date **13 Nov 2020**

PATIENT
Subject ID **12592014**
Site ID **1259**
Sex **Male**
Date of Birth **01JAN1949**
Diagnosis **Prostate Cancer**

SPECIMEN
Specimen ID **6209901099**
Sample Type **Slide Deck**
Site **Prostate**
Collection Date **29MAY2019**
Received Date **02NOV2020**
Visit Type **Archival Tumor Tissue**

**This is a QUALIFIED report. Sensitivity for the detection of alterations is reduced due to sample quality.**

## STUDY-RELATED ALTERATION(S) IDENTIFIED

| GENE | ALTERATION | STATUS |
|---|---|---|
| BRCA2 | None Detected | |
| FANCA | None Detected | |
| ATM | None Detected | |
| ATR | None Detected | |
| BRCA1 | None Detected | |
| CHEK2 | None Detected | |
| RAD51C | None Detected | |
| MRE11A | None Detected | |
| NBN | None Detected | |
| MLH1 | None Detected | |
| PALB2 | None Detected | |
| CDK12 | None Detected | |